Fig. 1

Upregulation of NatD in lung tissues correlates with enhanced invasiveness and poor prognosis of patients with lung cancer. a Quantitative real-time PCR analysis of NatD mRNA levels normalized to GAPDH in lung carcinoma (LC) and matched normal tissues (NT); n = 29, two-tailed Student’s t-test; P = 0.0073 compared with matched normal tissue control. b Representative images of H&E staining and immunohistochemical (IHC) staining of NatD in matched normal tissues (n = 147), human lung squamous carcinoma (n = 74), and lung adenocarcinoma (n = 73) tissue samples. Scale bars, 500 μm. c Total IHC score of NatD in matched normal tissues (NT) and lung carcinoma (LC); mean ± s.d. of 147 pairs of tissue samples; two-tailed Student’s t-test, **P < 0.01 compared with matched normal tissue control. d Percentage of lung cancer patients with high expression and low expression of NatD stratified according to lymph node status (N0 or N1–3) (n = 147); two-sided Pearson χ ² test, *P < 0.05. e Kaplan–Meier plots of overall survival of patients with lung cancer, stratified by NatD expression. Data were obtained from Kaplan–Meier plotter database⁴⁹; log-rank test, P < 0.0001